Lv5
1210 积分 2023-07-03 加入
Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases
9个月前
已完结
Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now?
9个月前
已完结
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis
9个月前
已完结
Sjögren's syndrome: Old and new therapeutic targets
9个月前
已完结
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
9个月前
已完结
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
9个月前
已完结
Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients
1年前
已完结
Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients
1年前
已完结
OP0045 DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL
1年前
已完结
皖公网安备34019202002308
